MET and non-small cell lung carcinoma: The INSIGHT-1 phase 1b/2 trial studied tepotinib plus gefitinib in patients with EGFR-mutated NSCLC that were T790M negative and MET overexpression (IHC 2+ or 3+) or MET amplified by FISH (GCN 5 or greater or MET/CEP 2 or greater).